3 ML cabotegravir 200 MG/ML Injection

RxCUI: 2588077
RxNorm name: 3 ML cabotegravir 200 MG/ML Injection
Display name: 3 ML cabotegravir 200 MG/ML Injection
Full name: 3 ML cabotegravir 200 MG/ML Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:48

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Cabenuva	CABOTEGRAVIR AND RILPIVIRINE	ViiV Healthcare Company	1698baf3-f895-4c42-a1b1-e9ee3f20da36	2025-11-26	Warnings, Adverse reactions	Exact identifier rxcui: 2588077
Apretude	CABOTEGRAVIR	ViiV Healthcare Company	4338428e-43d4-4e02-ac9d-bd98e738a7da	2025-04-11	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2588077

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
1698baf3-f895-4c42-a1b1-e9ee3f20da36	3 ML cabotegravir 200 MG/ML Injection	SCD	16	These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021	20251126
1698baf3-f895-4c42-a1b1-e9ee3f20da36	cabotegravir 600 MG per 3 ML Injection	SY	16	These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021	20251126
1698baf3-f895-4c42-a1b1-e9ee3f20da36	cabotegravir 600 MG in 3 ML Extended Release Injection	PSN	16	These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021	20251126
4338428e-43d4-4e02-ac9d-bd98e738a7da	cabotegravir 600 MG per 3 ML Injection	SY	8	These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use Initial U.S. Approval: 2021	20250411
4338428e-43d4-4e02-ac9d-bd98e738a7da	3 ML cabotegravir 200 MG/ML Injection	SCD	8	These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use Initial U.S. Approval: 2021	20250411
4338428e-43d4-4e02-ac9d-bd98e738a7da	cabotegravir 600 MG in 3 ML Extended Release Injection	PSN	8	These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use Initial U.S. Approval: 2021	20250411